Tacrolimus dry powder inhalation - TFF Pharmaceuticals
Alternative Names: Tac-Lac Inhalation Powder; Tacrolimus inhalation powder - TFF Pharmaceuticals; TFF TAC-LAC; TFF-TACLatest Information Update: 13 Aug 2024
At a glance
- Originator TFF Pharmaceuticals
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antiglaucomas; Antipsoriatics; Antirheumatics; Eye disorder therapies; Lactones; Macrolides; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Lung transplant rejection
- No development reported Asthma
Most Recent Events
- 06 Aug 2024 Updated efficacy and safety data from a phase II trial in Lung transplant rejection released by TFF Pharmaceuticals
- 14 May 2024 Updated efficacy data from a phase II trial in Lung transplant rejection released by TFF Pharmaceuticals
- 14 May 2024 TFF Pharmaceuticals expects to receive feedback from US FDA in second quarter regarding TFF TAC clinical development plan and next steps